Showing results (191-200 of 202) with videos related to
Sort By:
Pageof 21
Leukemia|June 22, 2011
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesS Hart, K C Goh, V Novotny-Diermayr, et al.Viruses|August 28, 2025
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant Staphylococcus epidermidis Periprosthetic Joint InfectionMelissa T Cammuso, Bradley W M Cook, D William Cameron, et al.Journal of Medicinal Chemistry|May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaAnthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.Neuro-Oncology|February 27, 2019
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendationsZachary Miklja, Amy Pasternak, Stefanie Stallard, et al.Plos One|July 14, 2022
A randomized control trial of high-dose micronutrient-antioxidant supplementation in healthy persons with untreated HIV infectionWendy L Wobeser, Joanne E McBane, Louise Balfour, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entryTaha Azad, Ragunath Singaravelu, Zaid Taha, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Nikolas T Martin, et al.BMJ Open|April 22, 2022
Building knowledge, optimising physical and mental health and setting up healthier life trajectories in South African women (Bukhali): a preconception randomised control trial part of the Healthy Life Trajectories Initiative (HeLTI)Shane A Norris, Catherine E Draper, Alessandra Prioreschi, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2024
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancerAndrew Dj Pearson, Steven G DuBois, Margaret E Macy, et al.Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.Pageof 21